Who is sponsoring NCT04454723?

NCT04454723 is sponsored by University of Oklahoma.

What drugs are being tested in NCT04454723?

Interventions in NCT04454723: Blood and/or platelet transfusion, Complete blood count (CBC) collection.

What condition does NCT04454723 study?

NCT04454723 studies Hematologic Malignancy.

Is NCT04454723 still recruiting?

NCT04454723 is currently completed. Last updated 5 March 2024.

Last reviewed 2024-03-05 · How we verify

NCT04454723: PalliaQOL

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Impact of Palliative Transfusions on Quality of Life in Patients With Blood Cancers on Hospice

Completed NA Last updated 5 March 2024

What this trial tests

NA trial testing Blood and/or platelet transfusion in Hematologic Malignancy in 20 participants. Completed in 17 August 2023.

Timeline

14 August 2020

Primary endpoint
16 August 2023

17 August 2023

Quick facts

Lead sponsor	University of Oklahoma
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	supportive care
Enrollment	20
Start date	14 August 2020
Primary completion	16 August 2023
Estimated completion	17 August 2023
Sites	1 location across United States

Drugs / interventions tested

Blood and/or platelet transfusion
Complete blood count (CBC) collection

Conditions studied

Hematologic Malignancy — all drugs for Hematologic Malignancy →

Sponsor

University of Oklahoma

Who can join

18 and older, any sex, with Hematologic Malignancy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this pilot research study is to evaluate the effectiveness of blood and platelet transfusions in improving symptoms and quality of life of patients enrolled in hospice.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem cell support.
Radford M, Estcourt LJ, Sirotich E, Pitre T, et al · · 2024 · cited 8× · PMID 38780066 · DOI 10.1002/14651858.cd011305.pub3
Challenges in hospice and end-of-life care in the transfusion-dependent patient.
Rodenbach R, Caprio T, Loh KP. · · 2024 · PMID 39644067 · DOI 10.1182/hematology.2024000560

Verify or expand the search:

Other recruiting trials for Hematologic Malignancy

Currently open trials in the same condition.

NCT06856226 — Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing · recruiting
NCT07511127 — Comparing the Efficacy of Different Durations of Maribavir Treatment Regimens in Allo-HSCT · Phase 3 · recruiting
NCT07413991 — Expressive Writing Program Among Young Adults With Blood Cancer · NA · active not recruiting
NCT06487247 — HEME Home Transfusion Program · NA · recruiting
NCT07035938 — T-cell Developmental Status in Patients With Malignant Hematological Tumors · recruiting

Other University of Oklahoma trials

Trials by the same sponsor.

NCT07219706 — Dietary Fiber and Time Restricted Eating · NA · recruiting
NCT07494773 — Topical Methylene Blue-Photodynamic Therapy (MB-PDT) for Burn Wound Infection · Phase 1, PHASE2 · not yet recruiting
NCT07014605 — Smoking Cessation Program for Lao People With HIV · NA · not yet recruiting
NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07491653 — Fiber mHealth Intervention for Prediabetes · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04454723 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Oklahoma
Last refreshed: 5 March 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04454723.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing